SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
Summary
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants were patients aged 15-65 years with high risk or relapsed/refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic neoplasms (MDS), diagnosed based on bone marrow morphology, immunophenotyping, genetic testing, and treatment response assessment. The experimental group received SHR2554 combined with azacitidine as an overlapped sequential combination with the mBuCy conditioning regimen, whereas the control group received the mBuCy conditioning regimen, both followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary endpoint is 1-year event-free survival (EFS). Secondary endpoints include 2-year overall survival, 2-year cumulative incidence of relapse, transplant-related mortality, incidence of acute/chronic GVHD, and safety profiles.
Timeline
- Start
- 2026-06
- Primary completion
- 2029-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | SHR2554 | Small molecule | 350 mg | — |
| Background | Busulfan | Small molecule | 0.8 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 1.8 g | — |
| Background | Cytarabine | Small molecule | 2 g | — |
| Background | Semustine | Small molecule | 250 mg/m2 | — |